N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Phase 2 N=109 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Inflammation and Pain Following Ocular Surgery
Primary: Absence of Anterior Chamber Cells at Day 15 (Visit 5) — 10; 12; 11; 27 Participants — p=0.4543
Phase 3 N=178 Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
Cataract
Primary: Visual Ability (VA) — 0.91; 0.87 units on a scale (LogMAR) — p=0.065
Phase 4 N=14 Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery
Retinal Detachment
Primary: Post Operative Pain Day 1 — 2.2; 1.0 score on a scale
Phase 3 N=520 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
Post Surgical Ocular Inflammation and Pain
Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105
N/A N=50 Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery
Strabismus
Primary: Average Pain Score Over the First 30 Post-operative Minutes Using the CHEOPS Scale — 6.36; 6.57; 6.58 units on a scale
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Phase 4 N=57 Postoperative Pain Control Following Vitreoretinal Surgery
Retinal Detachment · Proliferative Vitreoretinopathy · Retinoschisis
Primary: Mean Pain Score — 2.9; 3.8 units on a scale
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
Phase 2 N=256 Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
Inflammation · Pain · Cataract
Primary: Proportion of Subjects With Clearing of Anterior Inflammation — 18; 18; 13 Participants
Phase 3 N=514 Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation · Pain · Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 16; 46; 49 Participants
Phase 3 N=406 Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
Inflammation · Pain
Primary: Resolution of Anterior Chamber Cells (ACC). — 62; 33 Eyes — p=<0.001
N/A N=50 Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Cataract · Retinal Edema · Inflammation
Primary: Treatment of Inflammation Associated With Cataract Surgery — 0.01; 0.01 units on a scale
Phase 3 N=263 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Cataract Extraction
Primary: Resolution of Post Operative Inflammation — 58.0; 27.3 % of participants with a score of 0
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
Phase 3 N=326 Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation · Pain · Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 38; 29 Participants
Phase 3 N=378 Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain
Primary: Participants With ACC Count = 0 at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication — 48; 10 Participants — p=<0.001
Phase 3 N=248 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Cataract Extraction · Pain · Inflammation
Primary: Resolution of Post Operative Inflammation — 46.3; 25.6 % of participants with a score of 0
Phase 4 N=126 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Cataracts
Primary: Aqueous PGE2 Inhibition — 288.7; 320.4; 224.8 pg/ml
Phase 3 N=325 Evaluation of Efficacy and Safety of SDN-037
Inflammation and Pain Associated With Ocular Surgery
Primary: Subjects With an Anterior Chamber Cell Grade of 0 at Day 15 — 96; 30 Participants — p=<.0001
Phase 3 N=219 Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
Inflammation
Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 19; 13 participants — p=0.0014
Phase 4 N=126 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
Cataracts
Primary: Peak Aqueous Penetration — 688.87; 67.64; 447.1 ng/ml
Phase 3 N=219 Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
Inflammation
Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 18; 7 participants — p=<0.0001
Phase 3 N=407 Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
Inflammation · Pain
Primary: Resolution of Anterior Chamber Cells. — 64; 28 participants
Phase 3 N=156 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
Phase 2 N=35 Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control
Photorefractive Keratectomy · Myopia · Hyperopia
Primary: Pain as Recorded by the FACES Scale (Maximum) After First Surgery — 1.33; 1.27 units on a scale — p=0.538
Phase 2 N=37 A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
Post Surgical Ocular Inflammation
Primary: Assessment of Both Systemic and Ocular Adverse Events — 0; 3; 0; 0 Number of TEAE
Phase 2 N=132 A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain After Cataract Surgery
Primary: Number of Treatment Emergent Adverse Events — 4; 7; 3; 8 Participants